Advertisement
Product Releases
Advertisement

Nanotechnology Cancer Treatment

Tue, 07/06/2010 - 7:47am

Nano Cancer® Therapy is currently approved  in Europe for the treatment of brain tumors only, but studies are underway in prostate cancer, esophageal cancer and pancreatic cancer.

July 6, 2010

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy. The official notice of regulatory approval signifies that the authorized testing centers in Germany responsible for conformity evaluation of medical devices have completed their examination of the application submitted for market approval of Nano-Cancer® therapy and that the approved medical devices fulfill all requirements with regard to quality, safety and medical efficacy.

According to Medgadget, the treatment is based on energy transmission to biocompatible superparamagnetic nanoparticles in an alternating magnetic field, similar to the principles behind magnetic resonance imaging. The nanoparticles are very small bits of iron oxide suspended in a liquid, which are brought into the tumor with a regular cannula and then penetrate the tumor cells. When the magnetic field is applied they heat up—up to a temperature of 45 degrees Celcius if used for boosting of conventional radiation or chemotherapy, or up to 70 degrees Celcius when used by itself as thermoablation. Because the particles are absorbed by the tumor cells, surrounding healthy tissues are spared.

"This is a historic milestone for MagForce," exclaimed Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG, on news of the regulatory approval. "Over the past twenty years, the company has worked in close partnership with a number of partners in academia, particularly the Charité University Medical Center in Berlin, to develop this highly innovative therapeutic approach for treating solid tumors. Along this long road, Dr. Andreas Jordan, founder of the company and my colleague on the executive board, always remained true to his vision of an entirely new concept in cancer treatment based on recent advances in nanotechnology. In recognition of his many years of dedication, I am thus particularly delighted that, with regulatory approval received, a revolutionary new product in nanomedicine may now be brought to market."

The regulatory approval covers the treatment of brain tumors throughout the European Union. With this approval in hand, the company is now accelerating and strengthening its sales and marketing activities to introduce its new therapeutic procedure into the major European markets, starting with Germany, as well as moving its business model into the next stage.

For more information, visit www.magforce.de/english/home1.html

 

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading